Genmab — Oktober 2018
-
US klarede sig lidt bedre end jeg tænkte - men RoW er en decideret katastrofe. Og selv efter korrektionen er der tale om et decideret fald
-
US har ikke rigtig vækst længere og laver RoW det her nummer et kvartal mere - så når vi ikke 2.000
-
Der er rigtig mange ender, der ikke længere mødes, når vi taler om Genmab
-
LIge nu skal vi være heldige for at nå den nedre del af guidance
-
de har jo skrevet forklaring i egen meddelelse: The growth was partially offset by a one-time adjustment outside the U.S. related to accruals for retroactive pricing adjustments which negatively impacted this worldwide operational growth by 16 percentage points.
-
Det skulle ikke undre mig om vi får en præcisering af intervallet - for usd 2,3b er helt hen ude i skoven
-
sowise - prøv at regn på tallene. Det hænger slet ikke sammen
-
Det er en fuldtonet katastrofe
-
Er det 16% af ROW og US? Altså 80 Mio?
-
i så fald 580 minus 80 i rabat...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind